prazosin has been researched along with Alcohol Abuse in 33 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-four individuals seeking treatment for AUD participated in a six-week placebo-controlled study of prazosin and underwent an anticipatory anxiety task during fMRI scans at baseline and three weeks." | 9.34 | Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder. ( Adinoff, B; Bogenschutz, M; Boggs, KM; Clifford, J; Eck, M; Ling, J; Mayer, AR; Wilcox, CE; Witkiewitz, K, 2020) |
| "Prazosin (PRZ; an α1 -adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or "P"), and the combination of PRZ + NTX decreases alcohol drinking more effectively than does either drug alone." | 7.81 | Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2015) |
| "Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone." | 7.80 | Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014) |
| " Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring "P" rats), we tested whether a combination of NTX + prazosin is more effective in decreasing alcohol drinking than is either drug alone." | 7.79 | Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone. ( Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013) |
| "The findings indicate that alcohol withdrawal symptoms are a significant moderator of prazosin treatment response for alcohol use outcomes and for associated symptoms of alcohol craving, anxiety, and mood symptoms." | 5.41 | Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms. ( Angarita, GA; Fogelman, N; Fox, HC; Hermes, G; Milivojevic, V; Morgan, PM; Sinha, R; Wemm, S, 2021) |
| "Thirty-four individuals seeking treatment for AUD participated in a six-week placebo-controlled study of prazosin and underwent an anticipatory anxiety task during fMRI scans at baseline and three weeks." | 5.34 | Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder. ( Adinoff, B; Bogenschutz, M; Boggs, KM; Clifford, J; Eck, M; Ling, J; Mayer, AR; Wilcox, CE; Witkiewitz, K, 2020) |
| "Prazosin may attenuate stress cue-induced alcohol craving and anxiety during early abstinence while improving adrenergic and stress system function, effects which are independent of a history of lifetime anxiety disorders." | 5.34 | Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder. ( Angarita, GA; Fox, HC; Hermes, G; Milivojevic, V; Sinha, R, 2020) |
| "Ninety-three Veterans participating in a randomized, double-blind, placebo-controlled treatment study evaluating the efficacy of the alpha-adrenergic agonist prazosin completed measures assessing overt hostility, covert hostility, and suicidal ideation at baseline." | 5.27 | Suicidal ideation in military veterans with alcohol dependence and PTSD: The role of hostility. ( Gandelman, E; Kachadourian, LK; Petrakis, IL; Ralevski, E, 2018) |
| "The prazosin group (n = 9) versus the placebo group (n = 8) showed significantly lower alcohol craving, anxiety, and negative emotion following stress exposure." | 5.16 | Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. ( Anderson, GM; Fox, HC; Hansen, J; Kimmerling, A; Morgan, PT; Siedlarz, KM; Sinha, R; Tuit, K, 2012) |
| " The alpha-1 adrenoceptor antagonist prazosin has been investigated as a treatment for alcoholism and for chronic stress disorders that are frequently comorbid with alcoholism." | 3.91 | Effects of the Alpha-1 Antagonist Prazosin on KOR Agonist-Induced Reinstatement of Alcohol Seeking. ( Coen, K; Funk, D; Lê, AD; Tamadon, S, 2019) |
| "Prazosin decreases alcohol intake in P rats even in a situation that would be expected to increase alcohol drinking, namely following periods of alcohol deprivation." | 3.81 | Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse. ( Fischer, S; Froehlich, JC; Hausauer, B; Rasmussen, DD; Wise, B, 2015) |
| "Prazosin (PRZ; an α1 -adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or "P"), and the combination of PRZ + NTX decreases alcohol drinking more effectively than does either drug alone." | 3.81 | Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2015) |
| "Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone." | 3.80 | Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014) |
| " Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring "P" rats), we tested whether a combination of NTX + prazosin is more effective in decreasing alcohol drinking than is either drug alone." | 3.79 | Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone. ( Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013) |
| "To address this aspect of alcohol use disorder, 102 active-duty soldiers participating in command-mandated Army outpatient alcohol treatment were randomized to also receive the brain-penetrant alpha-1 adrenergic receptor antagonist prazosin or placebo for 13 weeks." | 3.30 | A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters. ( Crews, L; Daniels, C; Darnell, J; Goke, K; Hart, K; Hendrickson, R; Holmes, H; Mayer, C; Peskind, ER; Poupore, EL; Raskind, MA; Rasmussen, D; Saxon, A; Simpson, T; Terry, G; Thomas, RG; Williams, T, 2023) |
| "In Study 1, patients with Alcohol Use Disorder (AUD) (N = 45) with varying AW levels at treatment entry were assessed to examine AW effects on corticostriatal responses to stress, alcohol cue and neutral visual images with functional magnetic resonance imaging (fMRI)." | 3.11 | Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder. ( Angarita, G; Fogelman, N; Hermes, G; Seo, D; Sinha, R; Wemm, S, 2022) |
| "Veterans with comorbid alcohol dependence and PTSD (n = 96) were randomized to prazosin (16 mg) or placebo in a 12-week outpatient, double-blind clinical trial." | 2.90 | Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. ( Gueorguieva, R; McKee, SA; Petrakis, IL; Ralevski, E; Roberts, W; Verplaetse, TL, 2019) |
| "Ninety-two participants with alcohol use disorder but without posttraumatic stress disorder were randomly assigned to receive prazosin or placebo in a 12-week double-blind study." | 2.87 | Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. ( Lyons, R; Malte, CA; Millard, SP; Raskind, M; Saxon, AJ; Simpson, TL; Stappenbeck, C; Tell, D, 2018) |
| "Prazosin was not effective in treating PTSD symptoms, improving sleep, or reducing alcohol consumption overall in this dually diagnosed group." | 2.82 | Prazosin for Veterans with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence: A Clinical Trial. ( Arias, A; Desai, N; Gueorguieva, R; Jane, JS; O'Brien, E; Petrakis, IL; Ralevski, E; Sevarino, K; Southwick, S, 2016) |
| "Posttraumatic stress disorder (PTSD) and alcohol dependence (AD) commonly co-occur and are associated with greater symptom severity and costs than either disorder alone." | 2.80 | A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. ( Dietel, B; Lyons, R; Malte, CA; Pocock, I; Raskind, M; Saxon, AJ; Simpson, TL; Tell, D; Varon, D, 2015) |
| "Within the PTSD group, combat exposure was associated with increased drinking independent of the severity of PTSD symptoms." | 2.79 | Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder. ( Arias, AJ; Fuehrlein, B; Jane, JS; O'Brien, E; Petrakis, IL; Ralevski, E, 2014) |
| "Current medications for alcohol dependence (AD) show only modest efficacy." | 2.74 | A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. ( Ferguson, LC; Gross, CA; Hart, KL; Malte, CA; McBride, B; Meredith, CW; Raskind, M; Saxon, AJ; Simpson, TL, 2009) |
| "Individuals with alcohol use disorder (AUD) exhibit maladaptive responses of the hypothalamic-pituitary-adrenal (HPA) axis to stress, which has been linked to high rates of relapse to drinking among abstinent individuals." | 1.72 | Sex differences in α-adrenergic receptor function contribute to impaired hypothalamic metaplasticity following chronic intermittent ethanol exposure. ( Marty, VN; Munier, JJ; Spigelman, I, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 2 (6.06) | 29.6817 |
| 2010's | 19 (57.58) | 24.3611 |
| 2020's | 9 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Sinha, R | 6 |
| Andrade, C | 2 |
| Fogelman, N | 2 |
| Wemm, S | 2 |
| Angarita, G | 1 |
| Seo, D | 1 |
| Hermes, G | 3 |
| Munier, JJ | 1 |
| Marty, VN | 1 |
| Spigelman, I | 1 |
| Raskind, MA | 2 |
| Williams, T | 1 |
| Holmes, H | 1 |
| Hart, K | 1 |
| Crews, L | 1 |
| Poupore, EL | 1 |
| Thomas, RG | 1 |
| Darnell, J | 1 |
| Daniels, C | 1 |
| Goke, K | 1 |
| Hendrickson, R | 1 |
| Terry, G | 1 |
| Mayer, C | 1 |
| Simpson, T | 1 |
| Saxon, A | 1 |
| Rasmussen, D | 1 |
| Peskind, ER | 1 |
| Funk, D | 1 |
| Coen, K | 1 |
| Tamadon, S | 1 |
| Lê, AD | 1 |
| Wilcox, CE | 1 |
| Adinoff, B | 1 |
| Clifford, J | 1 |
| Ling, J | 1 |
| Witkiewitz, K | 1 |
| Mayer, AR | 1 |
| Boggs, KM | 1 |
| Eck, M | 1 |
| Bogenschutz, M | 1 |
| Milivojevic, V | 2 |
| Angarita, GA | 2 |
| Fox, HC | 3 |
| Morgan, PM | 1 |
| Hallgren, KA | 1 |
| Delker, BC | 1 |
| Simpson, TL | 5 |
| Haass-Koffler, CL | 1 |
| Swift, RM | 1 |
| Leggio, L | 1 |
| Kachadourian, LK | 1 |
| Gandelman, E | 1 |
| Ralevski, E | 5 |
| Petrakis, IL | 5 |
| Manhapra, A | 1 |
| Saxon, AJ | 4 |
| Stappenbeck, C | 1 |
| Malte, CA | 3 |
| Lyons, R | 2 |
| Tell, D | 2 |
| Millard, SP | 1 |
| Raskind, M | 4 |
| Verplaetse, TL | 1 |
| Roberts, W | 1 |
| Gueorguieva, R | 2 |
| McKee, SA | 1 |
| Kleinman, RA | 1 |
| Ostacher, MJ | 1 |
| Froehlich, JC | 4 |
| Hausauer, BJ | 1 |
| Rasmussen, DD | 5 |
| Fuehrlein, B | 1 |
| O'Brien, E | 2 |
| Jane, JS | 2 |
| Arias, AJ | 1 |
| Beckwith, LE | 1 |
| Kincaid, CL | 2 |
| Dietel, B | 1 |
| Pocock, I | 1 |
| Varon, D | 1 |
| Hausauer, B | 1 |
| Fischer, S | 1 |
| Wise, B | 1 |
| Desai, N | 1 |
| Arias, A | 1 |
| Sevarino, K | 1 |
| Southwick, S | 1 |
| Trovero, F | 1 |
| David, S | 1 |
| Bernard, P | 1 |
| Puech, A | 1 |
| Bizot, JC | 1 |
| Tassin, JP | 1 |
| Meredith, CW | 1 |
| McBride, B | 1 |
| Ferguson, LC | 1 |
| Gross, CA | 1 |
| Hart, KL | 1 |
| Anderson, GM | 1 |
| Tuit, K | 1 |
| Hansen, J | 1 |
| Kimmerling, A | 1 |
| Siedlarz, KM | 1 |
| Morgan, PT | 1 |
| Walker, BM | 1 |
| Koob, GF | 1 |
| Lee, H | 1 |
| Hosein, EA | 1 |
| Rovinski, B | 1 |
| Miyamae, M | 1 |
| Camacho, SA | 1 |
| Zhou, HZ | 1 |
| Diamond, I | 1 |
| Figueredo, VM | 1 |
| Pandey, SC | 1 |
| Piano, MR | 1 |
| Schwertz, DW | 1 |
| Davis, JM | 1 |
| Pandey, GN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)[NCT02109562] | Phase 3 | 354 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms[NCT04793685] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence[NCT00762710] | Phase 2 | 92 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders[NCT03894345] | Phase 1 | 20 participants (Anticipated) | Interventional | 2019-05-24 | Suspended (stopped due to COVID-19) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Negative change from baseline scores indicate improvement in the severity of illness.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| RBP-7000 90 mg | -0.868 |
| RBP-7000 120 mg | -0.914 |
| Placebo | -0.518 |
"The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor judgement, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| RBP-7000 90 mg | -15.367 |
| RBP-7000 120 mg | -16.456 |
| Placebo | -9.219 |
"An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date. AEs are determined by the Investigator to be related or not related to the study drug.~A serious AE (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Although a subject may have had 2 or more adverse experiences the subject is counted only once in a category. The same subject may appear in different categories." (NCT02109562)
Timeframe: Day 1 to Week 8
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| No TEAEs | 1 or more TEAEs | Related TEAE | Serious TEAE | Serious, related TEAE | TEAE causing discontinuation | Death | |
| Placebo | 37 | 81 | 50 | 1 | 0 | 3 | 0 |
| RBP-7000 120 mg | 26 | 91 | 65 | 1 | 0 | 2 | 0 |
| RBP-7000 90 mg | 34 | 81 | 58 | 0 | 0 | 0 | 0 |
At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period (NCT00762710)
Timeframe: 12 weeks
| Intervention | percentage of days heavy drinking (Mean) | |
|---|---|---|
| Baseline % Days Heavy Drinking | Final medication week % Days Heavy Drinking | |
| Placebo | 66.5 | 22.6 |
| Prazosin | 71.8 | 11.4 |
1 review available for prazosin and Alcohol Abuse
| Article | Year |
|---|---|
Noradrenergic targets for the treatment of alcohol use disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antag | 2018 |
14 trials available for prazosin and Alcohol Abuse
| Article | Year |
|---|---|
Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Craving; Humans; Prazosin; Substance Withdrawal Syndrome | 2022 |
A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Ethanol; Humans; Military Personnel; Prazosin; Su | 2023 |
Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; Alcoholism; Anticipation, Psychological; | 2020 |
Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenocorticotropic Hormone; Adult; Alcoholism; Anxiety; An | 2020 |
Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcohol Abstinence; Alcoholism; Anxiety; Central Ner | 2021 |
Effects of Initiating Abstinence from Alcohol on Daily Craving and Negative Affect: Results from a Pharmacotherapy Clinical Trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Affect; Alcohol Abstinence; Alcoholism; Craving; Fem | 2018 |
Suicidal ideation in military veterans with alcohol dependence and PTSD: The role of hostility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcoholism; Comorbidity; Double-Blind Method; Female | 2018 |
Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Adm | 2018 |
Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholi | 2019 |
Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Alcohol Drinking; Alcoholism; Comorbidity; Co | 2014 |
A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcoholism; Craving; Double-Blind Method; Female; Hu | 2015 |
Prazosin for Veterans with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence: A Clinical Trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcoholism; Diagnosis, Dual (Psychiatry); Double-Bli | 2016 |
A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Affect; Aged; Alcoholism; Double-Blind Method; Fema | 2009 |
Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcoholism; Anxiety; Blood Pressure; Cues; Diagnosti | 2012 |
18 other studies available for prazosin and Alcohol Abuse
| Article | Year |
|---|---|
Prazosin for Alcohol Use Disorder: A Clarification.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Humans; Prazosin | 2021 |
Prazosin for Alcohol Use Disorder: Reply to Sinha.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Humans; Prazosin | 2021 |
Sex differences in α-adrenergic receptor function contribute to impaired hypothalamic metaplasticity following chronic intermittent ethanol exposure.
Topics: Alcoholism; Animals; Corticotropin-Releasing Hormone; Ethanol; Female; Hypothalamo-Hypophyseal Syste | 2022 |
Effects of the Alpha-1 Antagonist Prazosin on KOR Agonist-Induced Reinstatement of Alcohol Seeking.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic | 2019 |
Prazosin for Alcohol Use Disorder: A Symptom-Driven Approach to the Choice of Intervention.
Topics: Alcoholism; Clinical Decision-Making; Humans; Prazosin; Secondary Prevention; Treatment Outcome | 2021 |
Is Pretreatment Blood Pressure a Marker of Prazosin Response in Posttraumatic Stress Disorder With Comorbid Alcohol Use Disorder?
Topics: Alcoholism; Blood Pressure; Comorbidity; Endophenotypes; Humans; Hypertension; Prazosin; Randomized | 2019 |
Prazosin for the Treatment of Alcohol Use Disorders.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin | 2018 |
Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin | 2019 |
Prazosin and Alcohol Use Disorder.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin | 2019 |
Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals | 2013 |
Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; | 2014 |
Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Disease Models, Animal; Male; Prazosin; R | 2015 |
Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Therapy, Combin | 2015 |
The Combination of Marketed Antagonists of α1b-Adrenergic and 5-HT2A Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcoholism; Amphetamine; Animals; Behavior, Animal; Cyprohe | 2016 |
alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Alcoholism; Animals; Conditio | 2008 |
Effect of chronic alcohol feeding and withdrawal on rat liver plasma membrane structure and function: a study of binding of [3H]prazosin to the membrane bound alpha 1-adrenergic receptor.
Topics: Alcoholism; Animals; Cell Membrane; Dose-Response Relationship, Drug; Ethanol; Humans; Liver; Prazos | 1983 |
Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pigs and rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Blood Pressure; Coronary Circulation; Creatine Kinase; Diasto | 1998 |
Effect of ethanol administration and withdrawal on serotonin receptor subtypes and receptor-mediated phosphoinositide hydrolysis in rat brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcohol Withdrawal Delirium; Alcoholism; Animals; Calcimycin | 1992 |